Medoclav (Amoxicillin, Clavulanic Acid)

Amoxicillin interferes with bacterial cell wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Clavulanic acid acts as a β‑lactamase inhibitor, protecting amoxicillin from enzymatic degradation by bacterial β‑lactamases, thereby extending its antibacterial activity against resistant strains.

The dosage of Medoclav is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function, and local antimicrobial guidelines. Only a qualified healthcare professional should set the appropriate dosing regimen.

Safety data for Medoclav in pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against possible risks and consider alternative therapies when appropriate. Consultation with obstetric and pediatric specialists is recommended before use in pregnant or nursing patients.

To place an order, submit an enquiry on the Medoclav product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Compared with plain amoxicillin, Medoclav adds clavulanic acid, which inhibits β‑lactamases and expands coverage to organisms that produce these enzymes. This makes it more effective against resistant strains such as certain Haemophilus, Staphylococcus aureus, and Escherichia coli, whereas other beta‑lactams without a β‑lactamase inhibitor may be less reliable in those cases.

Medoclav should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Proper cold‑chain handling ensures the stability and potency of the injectable product.

Medoclav is supplied as an intravenous injection solution. It is administered by a healthcare professional through a sterile IV line, typically diluted in an appropriate compatible fluid as directed by the prescribing information. Administration should follow aseptic technique and institutional infusion protocols.

The most serious adverse reactions include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, Clostridioides difficile‑associated colitis, significant hepatic injury, and hematologic abnormalities like neutropenia. Immediate medical attention is required if any of these events are suspected.

Medoclav is contraindicated in patients with a known hypersensitivity to amoxicillin, clavulanic acid, or any other β‑lactam antibiotics. Caution is also advised for individuals with a history of severe allergic reactions, hepatic impairment, or those taking interacting medications that could increase toxicity.